On June 10, 2025, Xilio Therapeutics, Inc. held its annual meeting where stockholders elected three directors, approved increasing authorized shares from 200 million to 600 million, and ratified Ernst & Young as the accounting firm. Voting results included 38.8 million in favor for the share increase and 40.7 million in favor of Ernst & Young.